Our Take
This is a vendor-published resource guide masquerading as industry analysis; no independent data supports the 'defining advantage' claim, and the piece offers no benchmarks, timelines, or failure case studies.
Why it matters
Sponsors running multi-site trials spend millions on lab infrastructure and data integrity. A poor central lab choice cascades into protocol delays and failed recruitment, but the market lacks transparent comparison frameworks.
Do this week
Trial sponsors: Audit your current central lab contract for turnaround time SLAs and sample rejection rates before the next protocol amendment window closes in Q3.
Central Labs Anchor Modern Trial Operations
Fierce Biotech has published a resource guide positioning central laboratories as essential infrastructure for clinical trials. The framing argues that as trials grow more complex—involving more sites, longer duration, and tighter regulatory oversight—centralized lab services have moved from operational convenience to strategic differentiator.
The piece cites three broad categories: scientific factors (assay standardization, data quality), operational factors (throughput and turnaround), and logistical factors (sample handling, chain of custody). No independent benchmarks are provided.
The Sponsor's Real Problem Isn't Lab Capability—It's Visibility
Central labs do standardize assay methodology across sites, reduce inter-lab variance, and simplify regulatory reporting. That is baseline table stakes, not a differentiator. What actually separates a functional partnership from a costly drag is turnaround time, sample rejection rates, and responsiveness to protocol amendments mid-trial. None of those metrics appear in this guide.
Sponsors routinely cite lab delays as a top three reason for trial timeline slippage, yet most evaluate labs on compliance pedigree and brand reputation rather than operational KPIs. A vendor-published resource that avoids naming benchmarks (sample-to-result SLAs, rejection rates by assay type, amendment response time) is not helping sponsors make that distinction.
How to Actually Evaluate a Central Lab Partnership
Ask for: historical turnaround times (p50 and p95, not average), rejection rates and root causes by assay, documented response time to protocol amendments, and customer references from trials closed in the last 18 months. Demand audited data, not reference panels.
Insist on pilot feasibility studies with your actual protocol and sample volumes before contract signature. Performance drift is real; a lab's historical speed means nothing if your trial's assay mix or sample volume exceeds their proven capacity.
Lock turnaround SLAs into the contract with penalty clauses tied to key milestones (enrollment hold-ups, interim analysis delays). Most lab contracts are cost-plus with soft timelines; that transfers all scheduling risk to the sponsor.
Finally, do not confuse accreditation with operational excellence. CAP or ISO certification confirms they won't corrupt samples; it does not confirm they will report results in 48 hours or handle 2,000 samples per week without backlog.